CTOs on the Move

Alexion Pharmaceuticals

www.alexion.com

 
Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Our shared purpose to serve patients in need drives us to find answers, change the world, and create a legacy. Alexion`s three highly innovative therapies treat patients with four severe and ultra-rare diseases, and we are committed to developing additional therapies that have the potential to transform patients` lives. Today, Alexion is advancing the most robust rare disease pipeline in the biotech industry, which, in addition to our complement and metabolic clinical programs, includes more than 30 diverse preclinical programs across ...
  • Number of Employees: 1K-5K
  • Annual Revenue: $500M-1 Billion
  • www.alexion.com
  • 100 College Street
    New Haven, CT USA 06510
  • Phone: 203.271.8198

Executives

Name Title Contact Details
Rick Braun
Associate Director, Go-to-Market IT Business Partner Profile
Lauren Iacono
Head of Digital and Social Communications Profile
Craig Mansfield
Director, Global Head of Security and Facilities Operations Profile
Frederic Lancaster
Deputy Chief Information Security Officer Profile
Susan Tyson
Associate Director - Security Business Solutions Profile

Similar Companies

Trillium Therapeutics

Trillium Therapeutics is a Etobicoke, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pathogen Detection Systems

Pathogen Detection Systems, Inc. is a Thunder Bay, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Audentes Therapeutics

Audentes is a biotechnology company committed to the development and commercialization of innovative new medicines for people with serious, rare muscle diseases. We are a passionate, energetic team driven by the goals of improving the lives of patients and building a successful business. We take pride in strong, global relationships with the patient, research, and medical communities.

Denali Therapeutics

Denali Therapeutics Inc. (“Denali”) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).

BioElectron Technology Corporation

BioElectron is a platform biotechnology company, with expertise in the electron transfer (redox) chemical reactions that underpin oxidative stress and inflammation in all biological systems.